In the UK, real-world data analyzed by Public Health England (PHE) show a high level of effectiveness for a single dose of Comirnaty, BioNTech (Nasdaq: BNTX) and Pfizer’s (NYSE: PFE) coronavirus vaccine.
The results, which provide an early look at how the vaccine is performing outside of a clinical trial setting, will reassure those who support a longer gap between the first and second dose.
Unlike other countries, the UK has broken with the tested administration schedule of the vaccine, recommending a longer 12-week gap between doses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze